Adolor to Begin Trial of Pain Candidate

The FDA has allowed Adolor to being Phase I testing for ADL5747, a novel oral compound that targets the Delta opioid receptor.

Adolor said it expects to begin testing in the first quarter of this year.

ADL5747 is the second delta compound that will enter clinical trials under Adolor's worldwide collaboration with Pfizer to develop novel pain compounds.